Despite cutting $1 off the price target, the firm still expects the stock to rally nearly 49%.
Vir Biotechnology has an underappreciated opportunity in the flu prevention market, JPMorgan said. Analyst Eric Joseph upgraded the stock to overweight from neutral. He shaved $1 off his price target to $34, which still implies an upside of 48.9% from Friday's close. "Vir Biotechnology holds long-term pipeline opportunities across multiple infectious disease indications including hepatitis B, and Influenza A," he said in a note to clients Monday.
The stock could see a more than 50% upside from the study, he said, but could all fall as much as 10% if the data does not live up to expectations. The company may need to provide more visibility on RNA for shares to move more on just the trial, Joseph added. Joseph forecasted a 2027 product launch with peak net collaboration revenue of $950 million. That comes out to $5 per share.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
NBA-worst Rockets beat Spurs to end 11-game losing streakTari Eason matched his season high with 20 points and the Houston Rockets ended an 11-game losing streak, beating the San Antonio Spurs 122-110 on Saturday night.
Read more »
BridgeBio’s stock rallies 50% on new data from dwarfism therapyShares of BridgeBio Pharma Inc. soared about 52% in premarket trading on Monday after the company shared positive data from a Phase 2 clinical trial about...
Read more »
50 Years Ago, a Forgotten Mission Landed on Mars🔄From the archive: Here’s why the Mars 3 mission deserves more acclaim than history ever gave it.
Read more »
8 Flattering Jeans Styles If You're Over 50Looking for the best jeans for women over 50? Style experts recommend their favorite fits and styles to go with blouses, boots, and more.
Read more »